This website is intended for UK Healthcare professionals only. Other UK residents please visit astrazeneca.co.uk

Setting eligible endometrial cancer patients on an innovative course

eligible endometrial cancer and the need for innovative treatment options^1-4

pMMR endometrial cancer is a complex and highly heterogeneous disease, associated with a poor prognosis, which accounts for 70-80% of all advanced or recurrent endometrial cancer patients^1-3

Only about 1 in 5 advanced/recurrent EC patients survive beyond 5 years^5,6

Multiple histologies and overlapping molecular subtypes of aEC respond differently to treatment^1,7,8,15

IO regimen outcomes seen in dMMR aEC have not been replicated in pMMR patients^4,9,10,20

PARP inhibition may complement the effects of IO + CP

cancer tumour surrounded by cells and signals

Images adapted from Stewart et al. (2018)

pMMR tumors are heterogeneous, with diverse genomic drivers. Compared to dMMR EC tumours, they have a lower tumour mutational burden, scarce immune infiltration and therefore limited ability to mount an antitumour response.^14-16

Immunotherapy + platinum chemotherapy drives direct tumour cell killing. However, blockade of PD-L1 alone provides limited immune response because of the reduced mutational burden and neoantigen load of pMMR tumours^{1,14,15,17-19}

PARP inhibition induces DNA damage and cell death which may enhance immune priming and stimulate robust antitumour immune responses.^11-13

Find out more about the efficacy and safety profile of the IMFINZI + Chemotherapy, with or without LYNPARZA, regimens here

Please refer to the SmPC for further information to minimise the risks associated with the use of the medicine before making any prescribing decisions.

Abbreviations:

IO: Immuno-oncology, CP: Carboplatin and Paclitaxel, pMMR: Proficient Mismatch repair, aEC: Advanced Endometrial cancer, PARP: poly-ADP ribose polymerase

Corr B, et al. Br Med J 2022;1 DOI: 10.1136/bmjmed-2022-000152.
Li X, et al. Path - Res. and prac 2023;248; 154647
Kelkar SS, et al. Gynecol Oncol Rep 2022;42:101026.
Kok PR, et al. ESMO Open. 2022 Dec;7(6):100635.
Cao S, et al. BMC Cancer 2023. DOI: 10.1186/s12885-022-10482-x.
Heffernan K, et al. Gynecol Oncol 2022;166:317–325.
Murali R, et al. Int J Gynecol Pathol 2019;38:S40–S63.
Jamieson A, et al. Ther Adv Med Oncol 2021;13:1–14.
Dio CD, et al. Gynecol Oncol 2023;169:27–33.
Fountzilas E, et al. ESMO Open 2019;4:e000474.
Stewart RA, et al. Cancer Res 2018;78:6717–6725.
Musacchio L, et al. Cancer Manag Res 2020;12:6123-6135.
Post CCB, et al. Crit Rev Oncol Hematol 2020;152:102973.
Rizzo A, et al. J Clin Med 2022;11:3912.
Yang Y, et al. Int J Gynaecol Obstet 2024;164:436–459.
Antill Y, et al. Cancer 2022;128 1157–1161.
Eskander RN, et al. Ther Adv Med Oncol 2021;13:1–9.
Liu T-Y, et al. Theranostics 2021;11:5365–5386.
El-ghazzi N, et al. Onco Targets Ther 2023;16:359–369.
Westin SN, et al. J Clin Oncol 2023;42:283–299.
Chon HS, et al. SGO Annual Meeting on Women’s Cancer 16–18 March 2024. San Diego, USA. Oral presentation.
Baurain J-F, et al. SGO Annual Meeting on Women’s Cancer 16–18 March 2024. San Diego, USA. Oral presentation.
Westin SN, et al. J Clin Oncol 2023;42:283–29. Supplementary appendix.
LYNPARZA® (olaparib) Summary of Product Characteristics.
IMFINZI® (durvalumab) Summary of Product Characteristics.

Indication

IMFINZI in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by treatment with:
- IMFINZI as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR)
- IMFINZI in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).
Lynparza in combination with durvalumab is indicated for the maintenance treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair proficient (pMMR) whose disease has not progressed on first-line treatment with durvalumab in combination with carboplatin and paclitaxel.

GB-68804 | DOP: September 2025

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling ‌‌‌0‌‌‌8‌‌‌‌‌0‌‌‌‌0‌‌‌ ‌‌7‌‌‌‌‌‌8‌‌‌3‌‌‌ ‌‌0‌‌‌‌‌0‌‌‌‌3‌‌‌‌3‌‌‌.

This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.

Cookie Policy